Charles Schwab Investment Management Inc. Increases Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Charles Schwab Investment Management Inc. lifted its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 3.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,139,252 shares of the biopharmaceutical company’s stock after acquiring an additional 35,926 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Sangamo Therapeutics were worth $1,162,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at approximately $28,000. Shelton Wealth Management LLC acquired a new position in shares of Sangamo Therapeutics during the fourth quarter worth $29,000. Sageworth Trust Co purchased a new stake in shares of Sangamo Therapeutics during the 4th quarter valued at $61,000. XTX Topco Ltd boosted its position in shares of Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Sangamo Therapeutics during the 3rd quarter worth $150,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on SGMO. Truist Financial decreased their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Jefferies Financial Group dropped their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, January 27th. Finally, StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Sangamo Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $5.17.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $0.82 on Monday. The company has a market capitalization of $184.26 million, a P/E ratio of -1.09 and a beta of 1.49. The business’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.41. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million. Analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.